Am J Transplant, Volume 20, Suppl 3 Archives - Page 100 of 223 - ATC Abstracts

2020 American Transplant Congress
Mid-Term Outcomes after Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
M. Okada¹, T. Tomosugi¹, T. Hiramitsu¹, S. Narumi¹, Y. Watarai¹, A. Kanda¹, K. Futamura¹, N. Goto¹, A. Takeda²
¹Nagoya Daini Red Cross Hospital, Nagoya, Japan, ²Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
*Purpose: De novo donor-specific HLA antibody (DSA) and antibody-mediated rejection (ABMR) are strongly associated with late allograft loss in renal transplant recipients. However, the impact…
2020 American Transplant Congress
Multi- National Survey among Nephrologists and Transplant Surgeons about the Suitability and Acceptance of the Marginal Live Kidney Donors with Family History of Kidney Disease
Z. Arabi¹, S. Kaysi², A. Altheaby¹, E. Elhassan¹, M. Bukhari³, A. Mateen¹, A. Hamad⁴
¹KAMC, Riyadh, Saudi Arabia, ²CHR Orleans, Orleans, France, ³Taif University, Taif, Saudi Arabia, ⁴The Regional Medical Center, Orangeburg, SC
*Purpose: Kidney transplantation from a living donor is the best treatment option for End Stage Kidney Disease. Considering the shortage of available organs, transplant centers…
2020 American Transplant Congress
Predictors of Kidney Transplant Evaluation Attendance
C. G. Ford¹, Y. Leyva¹, Y. Zhu², E. J. Croswell³, C. Puttarajappa⁴, M. A. Dew³, M. L. Unruh², Y. Ng², L. Myaskovsky¹
¹Center for Healthcare Equity in Kidney Disease, University of New Mexico Health Sciences Center, Albuquerque, NM, ²University of New Mexico School of Medicine, Albuquerque, NM, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA
*Purpose: Given that clinic non-attendance is associated with worse health outcomes for patients and increased burden for providers, we examined whether patient worry about harm…
2020 American Transplant Congress
MY-ATLAS: A Novel Simulation Algorithm for Liver Transplant Allocation
C. G. Rickert¹, H. Zhao², Z. Leung², M. Akan³, J. F. Markmann¹, S. Tayur³, H. Yeh¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²City University of Hong Kong, Hong Kong, China, ³Tepper School of Business, Carnegie Mellon University, Pittsburgh, PA
*Purpose: Currently, the primary tool for modeling expected outcomes from changes in allocation policy is the SRTR-run Liver Simulated Allocation Model (LSAM), which is neither…
2020 American Transplant Congress
Impact of the Baseline Anti-A/B IgG Titer on the Clinical Outcome in ABO-Incompatible Liver Transplantation
J. Lee¹, E. Kim¹, S. Yang¹, D. Kim², M. Ju³, J. Lee¹, M. Kim¹, S. Kim¹, D. Joo¹
¹Department of Transplantation Surgery, Severance Hospital, Seoul, Korea, Republic of, ²Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, ³Department of Surgery, Gangam Severance Hospital, Seoul, Korea, Republic of
*Purpose: The use of ABO incompatible (ABOi) living donors is an attractive solution for expanding the liver donor pool. We investigated the impact of the…
2020 American Transplant Congress
Predictors and Outcomes of Acute Graft versus Host Disease after Liver Transplant
A. Caines¹, D. Moonka², S. Nagai³, R. Salgia²
¹Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI, ²Hepatology, Henry Ford Health System, Detroit, MI, ³Transplant Surgery, Henry Ford Health System, Detroit, MI
*Purpose: Graft-versus-Host Disease (GVHD) is a rare complication of liver transplant (LT) with an estimated incidence of 0.1-2% per year and a high mortality. There…
2020 American Transplant Congress
Higher Probability of Living Donor Liver Transplantation is Associated with DSAs Having a Higher Median Meld at Transplant
D. Haakinson¹, S. Noreen², D. Stewart², R. Batra¹, G. Gan¹, Y. Deng¹, S. Kulkarni¹
¹Yale, New Haven, CT, ²UNOS, Richmond, VA
*Purpose: Recent studies show that outcomes of living donor liver transplantation (LDLT) are superior compared to those receiving deceased donor grafts. Access to deceased donor…
2020 American Transplant Congress
A Comprehensive Evaluation of Risk Factors for Pneumocystis Jiroveci Pneumonia in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
N. Permpalung¹, V. Kittipibul², P. Mekraksakit³, P. Rattanawong⁴, S. Nematollahi¹, S. Mehta-Steinke¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Miami/Jackson Memorial Hospital, Miami, FL, ³Texas Tech University Health Sciences, Lubbock, TX, ⁴Mayo Clinic, Phoenix, AZ
*Purpose: Pneumocytis jiroveci pneumonia (PJP) is an important opportunistic fungal infection in solid organ transplant (SOT) recipients that carries a significant morbidity and mortality. Several…
2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
H. Stamps, K. Linder, D. O'Sullivan, F. Cheema, H. Kutzler
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…
2020 American Transplant Congress
Clinical Features and Transplant Outcomes in Kidney Transplant Recipients with Renal Cell Carcinoma
C. Baek, H. Kim, S. Park
Asan Medical Center, Seoul, Korea, Republic of
*Purpose: Previous studies have recommended a 2-5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell…